{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:05:32Z","timestamp":1790683532642,"version":"4.1.0"},"reference-count":92,"publisher":"Asia Pacific Academy of Ophthalmology","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia Pac J Ophthalmol (Phila)"],"published-print":{"date-parts":[[2019]]},"DOI":"10.22608\/apo.2017436","type":"journal-article","created":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T03:38:27Z","timestamp":1513654707000},"source":"Crossref","is-referenced-by-count":14,"title":["Management of Retinopathy of Prematurity\u2014Use of Anti-VEGF Therapy"],"prefix":"10.22608","member":"9895","published-online":{"date-parts":[[2019]]},"reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev. 2008;84:77\u201282.","DOI":"10.1016\/j.earlhumdev.2007.11.009"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis. 2007;10:133\u2012140.","DOI":"10.1007\/s10456-007-9066-0"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Multicenter trial of cryotherapy for retinopathy of prematurity. Three-month outcome. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol. 1990;108:195\u2012204.","DOI":"10.1001\/archopht.1990.01070040047029"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;12:1684\u20121694.","DOI":"10.1001\/archopht.121.12.1684"},{"key":"ref=5","unstructured":"Good WV, Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233\u2012248;discussion, 248\u2012250."},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603\u2012615.","DOI":"10.1056\/NEJMoa1007374"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Tawse KL, Jeng-Miller KW, Baumal CR. Current practice patterns for treatment of retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retina. 2016;47:491\u2012495.","DOI":"10.3928\/23258160-20160419-16"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Mintz-Hittner HA, Kuffel RR. Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina. 2008;28:831\u2012838.","DOI":"10.1097\/IAE.0b013e318177f934"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Lee JY, Chae JB, Yang SJ, et al. Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol. 2010;248:1257\u20121262.","DOI":"10.1007\/s00417-010-1375-0"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Henaine-Berra A, Garcia-Aguirre G, Quiroz-Mercado H, et al. Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy. J AAPOS. 2014;18:120\u2012123.","DOI":"10.1016\/j.jaapos.2013.12.009"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Wu WC, Yeh PT, Chen SN, et al. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan. Ophthalmology. 2011;118:176\u2012183.","DOI":"10.1016\/j.ophtha.2010.04.018"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Axer-Siegel R, Snir M, Ron Y, et al. Intravitreal bevacizumab as supplemental treatment or monotherapy for severe retinopathy of prematurity. Retina. 2011;31:1239\u20121247.","DOI":"10.1097\/IAE.0b013e31820d4000"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Wu WC, Kuo HK, Yeh PT, et al. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan. Am J Ophthalmol. 2013;155:150\u2012158.e151.","DOI":"10.1016\/j.ajo.2012.06.010"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Harder BC, von Baltz S, Jonas JB, et al. Intravitreal low-dosage bevacizumab for retinopathy of prematurity. Acta Ophthalmol. 2014;92: 577\u2012581.","DOI":"10.1111\/aos.12266"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Yetik H, Gunay M, Sirop S, et al. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey. Graefes Arch Clin Exp Ophthalmol. 2015;253:1677\u20121683.","DOI":"10.1007\/s00417-014-2867-0"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Huang Q, Zhang Q, Fei P, et al. Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors. Ophthalmology. 2017;124:1156\u20121164.","DOI":"10.1016\/j.ophtha.2017.03.018"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Wallace DK, Kraker RT, Freedman SF, et al. Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study. JAMA Ophthalmol. 2017;135:654\u2012656.","DOI":"10.1001\/jamaophthalmol.2017.1055"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Chen SN, Lian I, Hwang YC, et al. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between ranibizumab and bevacizumab. Retina. 2015;35:667\u2012674.","DOI":"10.1097\/IAE.0000000000000380"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML, et al. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina. 2008;28(3 Suppl):S19\u2012S25.","DOI":"10.1097\/IAE.0b013e318159ec6b"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Cheng HC, Lee SM, Hsieh YT, et al. Efficacy of intravitreal injection of anti-vascular endothelial growth factor agents for stage 4 retinopathy of prematurity. Retina. 2015;35:660\u2012666.","DOI":"10.1097\/IAE.0000000000000359"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Park SW, Jung HH, Heo H. Fluorescein angiography of aggressive posterior retinopathy of prematurity treated with intravitreal anti-VEGF in large preterm babies. Acta Ophthalmol. 2014;92:810\u2012813.","DOI":"10.1111\/aos.12461"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Tasman W. Retinopathy of prematurity: do we still have a problem?: the Charles L. Schepens Lecture. Arch Ophthalmol. 2011;129:1083\u20121086.","DOI":"10.1001\/archophthalmol.2011.192"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Connor AJ, Papastavrou VT, Hillier RJ, et al. Ultra-low dose of intravitreal bevacizumab in the treatment of retinopathy of prematurity. J Pediatr Ophthalmol Strabismus. 2015;52:e20\u2012e21.","DOI":"10.3928\/01913913-20150421-11"},{"key":"ref=24","doi-asserted-by":"crossref","unstructured":"Kim J, Kim SJ, Chang YS, et al. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity. Retina. 2014;34:77\u201282.","DOI":"10.1097\/IAE.0b013e318296e26d"},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"Harder BC, von Baltz S, Jonas JB, et al. Intravitreal bevacizumab for retinopathy of prematurity. J Ocul Pharmacol Ther. 2011;27:623\u2012627.","DOI":"10.1089\/jop.2011.0060"},{"key":"ref=26","doi-asserted-by":"crossref","unstructured":"Baumal CR, Goldberg RA, Fein JG. Primary intravitreal ranibizumab for high-risk retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retina. 2015;46:432\u2012438.","DOI":"10.3928\/23258160-20150422-05"},{"key":"ref=27","doi-asserted-by":"crossref","unstructured":"Karaca C, Oner AO, Mirza E, et al. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity. JAMA Ophthalmol. 2013;131:1099\u20121101.","DOI":"10.1001\/jamaophthalmol.2013.400"},{"key":"ref=28","doi-asserted-by":"crossref","unstructured":"Wong RK, Hubschman S, Tsui I. Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina. 2015;35:675\u2012680.","DOI":"10.1097\/IAE.0000000000000578"},{"key":"ref=29","doi-asserted-by":"crossref","unstructured":"Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695.e1\u2012e15.","DOI":"10.1016\/j.ophtha.2006.05.064"},{"key":"ref=30","doi-asserted-by":"crossref","unstructured":"Yonekawa Y, Wu WC, Nitulescu CE, et al. Progressive retinal detachment in infants with retinopathy of prematurity treated with intravitreal bevacizumab or ranibizumab. Retina. May 3, 2017. [Epub ahead of print].","DOI":"10.1097\/IAE.0000000000001685"},{"key":"ref=31","doi-asserted-by":"crossref","unstructured":"Law JC, Recchia FM, Morrison DG, et al. Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. J AAPOS. 2010;14:6\u201210.","DOI":"10.1016\/j.jaapos.2009.10.011"},{"key":"ref=32","doi-asserted-by":"crossref","unstructured":"Xu Y, Zhang Q, Kang X, et al. Early vitreoretinal surgery on vascularly active stage 4 retinopathy of prematurity through the preoperative intravitreal bevacizumab injection. Acta Ophthalmol. 2013;91:e304\u2012e310.","DOI":"10.1111\/aos.12055"},{"key":"ref=33","doi-asserted-by":"crossref","unstructured":"Kusaka S, Shima C, Wada K, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol. 2008;92:1450\u20121455.","DOI":"10.1136\/bjo.2008.140657"},{"key":"ref=34","doi-asserted-by":"crossref","unstructured":"Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina. 2006;26:699\u2012700.","DOI":"10.1097\/01.iae.0000225351.87205.69"},{"key":"ref=35","doi-asserted-by":"crossref","unstructured":"Atchaneeyasakul LO, Trinavarat A. Choroidal ruptures after adjuvant intravitreal injection of bevacizumab for aggressive posterior retinopathy of prematurity. J Perinatol. 2010;30:497\u2012499.","DOI":"10.1038\/jp.2009.166"},{"key":"ref=36","doi-asserted-by":"crossref","unstructured":"Jalali S, Balakrishnan D, Zeynalova Z, et al. Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian Twin Cities Retinopathy of Prematurity Screening database report number 5. Arch Dis Child Fetal Neonatal Ed. 2013;98:F327\u2012F333.","DOI":"10.1136\/archdischild-2012-302365"},{"key":"ref=37","doi-asserted-by":"crossref","unstructured":"Chhablani J, Rani PK, Balakrishnan D, et al. Unusual adverse choroidal reaction to intravitreal bevacizumab in aggressive posterior retinopathy of prematurity: the Indian Twin Cities ROP Screening (ITCROPS) data base report number 7. Semin Ophthalmol. 2014;29:222\u2012225.","DOI":"10.3109\/08820538.2013.835842"},{"key":"ref=38","doi-asserted-by":"crossref","unstructured":"Honda S, Hirabayashi H, Tsukahara Y, et al. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2008;246:1061\u20121063.","DOI":"10.1007\/s00417-008-0786-7"},{"key":"ref=39","doi-asserted-by":"crossref","unstructured":"Kong L, Mintz-Hittner HA, Penland RL, et al. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol. 2008;126:1161\u20121163.","DOI":"10.1001\/archophthalmol.2008.1"},{"key":"ref=40","doi-asserted-by":"crossref","unstructured":"Hairston RJ, Maguire AM, Vitale S, et al. Morphometric analysis of pars plana development in humans. Retina. 1997;17:135\u2012138.","DOI":"10.1097\/00006982-199703000-00009"},{"key":"ref=41","doi-asserted-by":"crossref","unstructured":"Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114:855\u2012859.","DOI":"10.1016\/j.ophtha.2007.01.017"},{"key":"ref=42","doi-asserted-by":"crossref","unstructured":"Miki K, Miki A, Matsuoka M, et al. Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. Ophthalmology. 2009;116:1748\u20121754.","DOI":"10.1016\/j.ophtha.2009.05.020"},{"key":"ref=43","doi-asserted-by":"crossref","unstructured":"Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2012;153:327\u2012333.e321.","DOI":"10.1016\/j.ajo.2011.07.005"},{"key":"ref=44","doi-asserted-by":"crossref","unstructured":"Hoerster R, Muether P, Dahlke C, et al. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol. 2013;91:e74\u2012e75.","DOI":"10.1111\/j.1755-3768.2012.02469.x"},{"key":"ref=45","unstructured":"Lee SJ, Kim SY, Yoo BC, et al. Plasma level of vascular endothelial growth factor in retinopathy of prematurity after intravitreal injection of bevacizumab. Invest Ophthalmol Vis Sci. 2011;52:3165."},{"key":"ref=46","doi-asserted-by":"crossref","unstructured":"Zhou Y, Jiang Y, Bai Y, et al. Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab. Graefes Arch Clin Exp Ophthalmol. 2016;254:31\u201236.","DOI":"10.1007\/s00417-015-2996-0"},{"key":"ref=47","doi-asserted-by":"crossref","unstructured":"H\u00e5rd AL, Hellstr\u00f6m A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment - a review. Acta Paediatr. 2011;100: 1523\u20121527.","DOI":"10.1111\/j.1651-2227.2011.02445.x"},{"key":"ref=48","doi-asserted-by":"crossref","unstructured":"H\u00e5rd AL, Hellstr\u00f6m A. On the use of antiangiogenetic medications for retinopathy of prematurity. Acta Paediatr. 2011;100:1063\u20121065.","DOI":"10.1111\/j.1651-2227.2011.02330.x"},{"key":"ref=49","doi-asserted-by":"crossref","unstructured":"Micieli JA, Micieli A, Smith AF. Identifying systemic safety signals following intravitreal bevacizumab: systematic review of the literature and the Canadian Adverse Drug Reaction Database. Can J Ophthalmol. 2010;45:231\u2012238.","DOI":"10.3129\/i10-027"},{"key":"ref=50","doi-asserted-by":"crossref","unstructured":"Compernolle V, Brusselmans K, Acker T, et al. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med. 2002; 8:702\u2012710.","DOI":"10.1038\/nm721"},{"key":"ref=51","doi-asserted-by":"crossref","unstructured":"Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035\u20121047.","DOI":"10.1016\/j.ophtha.2005.02.007"},{"key":"ref=52","doi-asserted-by":"crossref","unstructured":"Menke MN, Framme C, Nelle M, et al. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease. BMC Ophthalmol. 2015;15:20.","DOI":"10.1186\/s12886-015-0001-7"},{"key":"ref=53","doi-asserted-by":"crossref","unstructured":"Erol MK, Coban DT, Sari ES, et al. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity. Arq Bras Oftalmol. 2015;78:340\u2012343.","DOI":"10.5935\/0004-2749.20150090"},{"key":"ref=54","doi-asserted-by":"crossref","unstructured":"Glade Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children\u2019s Oncology Group study. J Clin Oncol. 2008;26:399\u2012405.","DOI":"10.1200\/JCO.2007.11.9230"},{"key":"ref=55","doi-asserted-by":"crossref","unstructured":"Reism\u00fcller B, Azizi AA, Peyrl A, et al. Feasibility and tolerability of bevacizumab in children with primary CNS tumors. Pediatr Blood Cancer. 2010;54:681\u2012686.","DOI":"10.1002\/pbc.22409"},{"key":"ref=56","doi-asserted-by":"crossref","unstructured":"Hwang EI, Jakacki RI, Fisher MJ, et al. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer. 2013;60:776\u2012782.","DOI":"10.1002\/pbc.24297"},{"key":"ref=57","doi-asserted-by":"crossref","unstructured":"Pillay Smiley N, Alden T, Hartsell W, et al. Severe radiation necrosis successfully treated with bevacizumab in an infant with low-grade glioma and tumor-associated intractable trigeminal neuralgia. Pediatr Blood Cancer. 2016;63:1671\u20121673.","DOI":"10.1002\/pbc.26055"},{"key":"ref=58","doi-asserted-by":"crossref","unstructured":"Millan NC, Poveda MJ, Cruz O, et al. Safety of bevacizumab in patients younger than 4 years of age. Clin Transl Oncol. 2016;18:464\u2012468.","DOI":"10.1007\/s12094-015-1389-5"},{"key":"ref=59","doi-asserted-by":"crossref","unstructured":"Geloneck MM, Chuang AZ, Clark WL, et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol. 2014;132:1327\u20121333.","DOI":"10.1001\/jamaophthalmol.2014.2772"},{"key":"ref=60","doi-asserted-by":"crossref","unstructured":"Morin J, Luu TM, Superstein R, et al. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics. 2016;137:e20153218.","DOI":"10.1542\/peds.2015-3218"},{"key":"ref=61","doi-asserted-by":"crossref","unstructured":"Lien R, Yu MH, Hsu KH, et al. Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment. PLoS One. 2016;11:e0148019.","DOI":"10.1371\/journal.pone.0148019"},{"key":"ref=62","doi-asserted-by":"crossref","unstructured":"Toy BC, Schachar IH, Tan GS, et al. Chronic vascular arrest as a predictor of bevacizumab treatment failure in retinopathy of prematurity. Ophthalmology. 2016;123:2166\u20122175.","DOI":"10.1016\/j.ophtha.2016.06.055"},{"key":"ref=63","doi-asserted-by":"crossref","unstructured":"Hwang CK, Hubbard GB, Hutchinson AK, et al. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology. 2015;122:1008\u20121015.","DOI":"10.1016\/j.ophtha.2014.12.017"},{"key":"ref=64","unstructured":"Mueller B, Salchow DJ, Waffenschmidt E, et al. Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone. Br J Ophthalmol. 2017;101:365\u2012370."},{"key":"ref=65","doi-asserted-by":"crossref","unstructured":"Karkhaneh R, Khodabande A, Riazi-Eafahani M, et al. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity. Acta Ophthalmol. 2016;94:e417\u2012e420.","DOI":"10.1111\/aos.13008"},{"key":"ref=66","doi-asserted-by":"crossref","unstructured":"Zhang G, Yang M, Zeng J, et al. Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity. Retina. 2017;37:710\u2012717.","DOI":"10.1097\/IAE.0000000000001241"},{"key":"ref=67","doi-asserted-by":"crossref","unstructured":"Coats DK, Miller AM, Brady McCreery KM, et al. Involution of threshold retinopathy of prematurity after diode laser photocoagulation. Ophthalmology. 2004;111:1894\u20121898.","DOI":"10.1016\/j.ophtha.2004.02.005"},{"key":"ref=68","doi-asserted-by":"crossref","unstructured":"Lorenz B, Stieger K, J\u00e4ger M, et al. Retinal vascular development with 0.312 mg intravitreal bevacizumab to treate severe posterior retinopathy of prematurity: a longitudinal fluorescein angiographic study. Retina. 2017; 37:97\u2012111.","DOI":"10.1097\/IAE.0000000000001126"},{"key":"ref=69","doi-asserted-by":"crossref","unstructured":"Hu J, Blair MP, Shapiro MJ, et al. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012;130:1000\u20121006.","DOI":"10.1001\/archophthalmol.2012.592"},{"key":"ref=70","unstructured":"Lee BJ, Kim JH, Heo H, et al. Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity. Eye (Lond). 2012;26:903\u2012909; quiz, 910."},{"key":"ref=71","doi-asserted-by":"crossref","unstructured":"Ittiara S, Blair MP, Shapiro MJ, et al. Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab. J AAPOS. 2013;17:323\u2012325.","DOI":"10.1016\/j.jaapos.2013.01.004"},{"key":"ref=72","doi-asserted-by":"crossref","unstructured":"Snyder LL, Garcia-Gonzalez JM, Shapiro MJ, et al. Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging Retina. 2016;47:280\u2012283.","DOI":"10.3928\/23258160-20160229-12"},{"key":"ref=73","doi-asserted-by":"crossref","unstructured":"Hajrasouliha AR, Garcia-Gonzales JM, Shapiro MJ, et al. Reactivation of retinopathy of prematurity three years after treatment with bevacizumab. Ophthalmic Surg Lasers Imaging Retina. 2017;48:255\u2012259.","DOI":"10.3928\/23258160-20170301-10"},{"key":"ref=74","doi-asserted-by":"crossref","unstructured":"Li XJ, Yang XP, Sun S, et al. Intravitreal ranibizumab for aggressive posterior retinopathy of prematurity. Chin Med J (Engl). 2016;129:2879\u20122881.","DOI":"10.4103\/0366-6999.194638"},{"key":"ref=75","doi-asserted-by":"crossref","unstructured":"Alyama\u00e7 Sukgen E, \u00c7\u00f6mez A, Ko\u00e7luk Y, et al. The process of retinal vascularization after anti-VEGF treatment in retinopathy of prematurity: a comparison study between ranibizumab and bevacizumab. Ophthalmologica. 2016;236:139\u2012147.","DOI":"10.1159\/000449530"},{"key":"ref=76","doi-asserted-by":"crossref","unstructured":"Lyu J, Zhang Q, Chen CL, et al. Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy: timing and risk factors. Invest Ophthalmol Vis Sci. 2017;58:1719\u20121725.","DOI":"10.1167\/iovs.16-20680"},{"key":"ref=77","doi-asserted-by":"crossref","unstructured":"Jang SY, Choi KS, Lee SJ. Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zone 1 plus retinopathy of prematurity. J AAPOS. 2010;14:457\u2012459.","DOI":"10.1016\/j.jaapos.2010.05.011"},{"key":"ref=78","doi-asserted-by":"crossref","unstructured":"Avery RL. Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both? J AAPOS. 2012;16:2\u20124.","DOI":"10.1016\/j.jaapos.2011.11.002"},{"key":"ref=79","doi-asserted-by":"crossref","unstructured":"Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897\u20121908.","DOI":"10.1056\/NEJMoa1102673"},{"key":"ref=80","doi-asserted-by":"crossref","unstructured":"Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119: 1399\u20121411.","DOI":"10.1016\/j.ophtha.2012.04.015"},{"key":"ref=82","doi-asserted-by":"crossref","unstructured":"Lin CJ, Tsai YY. Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity. Clin Ophthalmol. 2016;10:1323\u20121327.","DOI":"10.2147\/OPTH.S110717"},{"key":"ref=83","doi-asserted-by":"crossref","unstructured":"Lepore D, Quinn GE, Molle F, et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology. 2014;121:2212\u20122219.","DOI":"10.1016\/j.ophtha.2014.05.015"},{"key":"ref=84","doi-asserted-by":"crossref","unstructured":"Fierson WM, American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, et al. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2013;131: 189\u2012195.","DOI":"10.1542\/peds.2012-2996"},{"key":"ref=85","doi-asserted-by":"crossref","unstructured":"International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005;123:991\u2012999.","DOI":"10.1001\/archopht.123.7.991"},{"key":"ref=86","doi-asserted-by":"crossref","unstructured":"Beer PM, Wong SJ, Hammad AM, et al. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina. 2006;26:871\u2012876.","DOI":"10.1097\/01.iae.0000233327.68433.02"},{"key":"ref=87","doi-asserted-by":"crossref","unstructured":"Mintz-Hittner HA. Avastin as monotherapy for retinopathy of prematurity. J AAPOS. 2010;14:2\u20123.","DOI":"10.1016\/j.jaapos.2009.12.002"},{"key":"ref=88","doi-asserted-by":"crossref","unstructured":"Mintz-Hittner HA. Intravitreal pegaptanib as adjunctive treatment for stage 3+ ROP shown to be effective in a prospective, randomized, controlled multicenter clinical trial. Eur J Ophthalmol. 2012;22:685\u2012686.","DOI":"10.5301\/ejo.5000176"},{"key":"ref=89","doi-asserted-by":"crossref","unstructured":"Hellstrom A, Perruzzi C, Ju M, et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A. 2001;98:5804\u20125808.","DOI":"10.1073\/pnas.101113998"},{"key":"ref=90","doi-asserted-by":"crossref","unstructured":"Bancalari A, Schade R, Mu\u00f1oz T, et al. Oral propranolol in early stages of retinopathy of prematurity. J Perinat Med. 2016;44:499\u2012503.","DOI":"10.1515\/jpm-2015-0357"},{"key":"ref=91","doi-asserted-by":"crossref","unstructured":"Neu J, Afzal A, Pan H, et al. The dipeptide Arg-Gln inhibits retinal neovascularization in the mouse model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2006;47:3151\u20123155.","DOI":"10.1167\/iovs.05-1473"},{"key":"ref=92","doi-asserted-by":"crossref","unstructured":"Connor KM, SanGiovanni JP, Lofqvist C, et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med. 2007;13:868\u2012873.","DOI":"10.1038\/nm1591"},{"key":"ref=93","doi-asserted-by":"crossref","unstructured":"Wang SK, Callaway NF, Wallenstein MB, et al. SUNDROP: six years of screening for retinopathy of prematurity with telemedicine. Can J Ophthalmol. 2015;50:101\u2012106.","DOI":"10.1016\/j.jcjo.2014.11.005"}],"container-title":["Asia-Pacific Journal of Ophthalmology"],"original-title":[],"deposited":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T13:28:07Z","timestamp":1603546087000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/apjoo\/Fulltext\/2018\/01000\/Management_of_Retinopathy_of_Prematurity_Use_of.10.aspx"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":92,"URL":"https:\/\/doi.org\/10.22608\/apo.2017436","relation":{},"ISSN":["2162-0989","2162-0989"],"issn-type":[{"value":"2162-0989","type":"print"},{"value":"2162-0989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}